Walleye Capital LLC Krystal Biotech, Inc. Call Options Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $122,289 - $149,562	700 Added 50.0%	2,100 $381,000
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $214,368 - $257,095	1,400 New	1,400 $257,000
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $47,088 - $78,192	600 Added 18.18%	3,900 $457,000
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $238,887 - $278,091	3,300 New	3,300 $264,000
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $45,394 - $57,680	700 New	700 $49,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.